Key statistics
On Monday, Cosmos Health Inc (V67A:DUS) closed at 0.3156, 16.98% above the 52 week low of 0.2698 set on Apr 22, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.3142 |
|---|---|
| High | 0.3156 |
| Low | 0.3142 |
| Bid | 0.3156 |
| Offer | 0.332 |
| Previous close | 0.317 |
| Average volume | 5.71k |
|---|---|
| Shares outstanding | 34.92m |
| Free float | 24.41m |
| P/E (TTM) | -- |
| Market cap | 13.38m USD |
| EPS (TTM) | -0.7121 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 18:30 GMT.
More ▼
Announcements
- Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies
- Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
- Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
- Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
- Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets
- Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
- Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M
- Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
- Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million
- Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
More ▼
